Becton, Dickinson and Company has completed the spin-off of its Biosciences and Diagnostics Solutions business and its subsequent merger with Waters Corporation. The transaction resulted in a $4 billion cash payment to the company, which management intends to allocate equally toward share repurchases and debt reduction. This significant liquidity event provides a clear path for strengthening the balance sheet and enhancing shareholder returns in the near term.
